Inotiv Inc is a leading provider of preclinical and clinical research services, specializing in laboratory animal research and drug development solutions for the pharmaceutical and biotechnology industries. The company offers a wide range of scientific services, including toxicology, pathology, and pharmacology, aimed at helping clients navigate the complexities of medical research and bring new therapies to market. By leveraging advanced technologies and expertise, Inotiv supports clients in designing and executing studies that ensure the safety and efficacy of therapeutic products, thereby advancing healthcare innovation. Read More
American Lithium Minerals, Inc. (OTC: AMLM) continues advancing its strategy to build shareholder value across a diversified portfolio of critical minerals, precious metals , and energy transition assets after announcing a Letter of Intent (LOI) that could lead to the spinout and public listing of its 100%-owned Piscau-North Polymetallic Project in Quebec.
Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas. The support of these stakeholders speaks to their confidence in the strength of Inotiv’s business.
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
